Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
NYU Langone Health · Icahn School of Medicine at Mount Sinai · +33 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
2,200
total citations
- FWCI
- 201.93
- Percentile
- 100%
- References
- 32
Citations per year
Authors
35- AVArjun Vasant BalarCorresponding
NYU Langone Health
- MDMatthew D. Galsky
Icahn School of Medicine at Mount Sinai
- JEJonathan E. Rosenberg
Memorial Sloan Kettering Cancer Center
- TPThomas Powles
University College London, Queen Mary University of London, The Royal Free Hospital, Barts Health NHS Trust
- DPDaniel P. Petrylak
Yale University, Smilow Cancer Hospital
Topics & keywords
Topics
Keywords
- Atezolizumab
- Medicine
- Metastatic Urothelial Carcinoma
- Clinical endpoint
- Oncology
- Internal medicine
- Cisplatin
- Chemotherapy
No related works found for this paper.